AUTHOR=Peng Xing-Jie , Hei Gang-Rui , Li Ran-Ran , Yang Ye , Liu Chen-Chen , Xiao Jing-Mei , Long Yu-Jun , Shao Ping , Huang Jing , Zhao Jing-Ping , Wu Ren-Rong 

TITLE=The Association Between Metabolic Disturbance and Cognitive Impairments in Early-Stage Schizophrenia

JOURNAL=Frontiers in Human Neuroscience

VOLUME=14

YEAR=2021

URL=https://www.frontiersin.org/journals/human-neuroscience/articles/10.3389/fnhum.2020.599720

DOI=10.3389/fnhum.2020.599720

ISSN=1662-5161

ABSTRACT=<p><bold>Background</bold>: Cognitive impairment is one of the core symptoms of schizophrenia, which is considered to be significantly correlated to prognosis. In recent years, many studies have suggested that metabolic disorders could be related to a higher risk of cognitive defects in a general setting. However, there has been limited evidence on the association between metabolism and cognitive function in patients with early-stage schizophrenia.</p><p><bold>Methods</bold>: In this study, we recruited 172 patients with early-stage schizophrenia. Relevant metabolic parameters were examined and cognitive function was evaluated by using the MATRICS Consensus Cognitive Battery (MCCB) to investigate the relationship between metabolic disorder and cognitive impairment.</p><p><bold>Results</bold>: Generally, the prevalence of cognitive impairment among patients in our study was 84.7% (144/170), which was much higher than that in the general population. Compared with the general Chinese setting, the study population presented a higher proportion of metabolic disturbance. Patients who had metabolic disturbance showed no significant differences on cognitive function compared with the other patients. Correlation analysis showed that metabolic status was significantly correlated with cognitive function as assessed by the cognitive domain scores (<italic>p</italic> &lt; 0.05), while such association was not found in further multiple regression analysis.</p><p><bold>Conclusions</bold>: Therefore, there may be no association between metabolic disorder and cognitive impairment in patients with early-stage schizophrenia.</p><p><bold>Trial Registration</bold>: <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/" xmlns:xlink="http://www.w3.org/1999/xlink">Clinicaltrials.gov</ext-link>, NCT02880462. Registered August 26, 2016.</p>